www.tajpharma.com

Dermapar® is an innovative, non-opioid analgesic that provides up to three days of postsurgical pain relief* when used as part of a multimodal treatmentregimen. Multimodal therapy aims to relieve postsurgical pain by using a combination of anesthetic/analgesic drugs that act at different sites within the central and peripheral nervous systems in an effort to effectively reduce pain.

NEW SINGLE-DOSE, NON-OPIOID DERMAPAR®
(Bupivacaine Liposome Injectable Suspension)
ENHANCING POSTSURGICAL PAIN CONTROL

SINGLE-DOSE, NON-OPIOID
NEW DERMAPAR®
(Bupivacaine Liposome Injectable Suspension)
ENHANCING POSTSURGICAL PAIN CONTROL

Dermapar® — The Only Single-Dose Local Analgesic That Controls Pain for Up to 72 Hours.
Dermapar is indicated for administration into the surgical site to produce postsurgical analgesia.

Dermapar is a local analgesic that utilizes bupivacaine in combination with the proven product delivery platform, **A single intraoperative injection treats pain at the source with reduced opioid requirements for up to 72 hours.**
Pivotal studies have demonstrated the safety and efficacy of Dermapar in patients undergoing bunionectomy and hemorrhoidectomy procedures. The clinical benefit of the attendant decrease in opioid consumption was not demonstrated.

When used as part of a multimodal treatment regimen, **Dermapar can provide non-opioid pain control that lasts as long as the most intense postsurgical pain, without the need for catheters, pumps, or other delivery devices**.

Dermapar is indicated for administration into the surgical site to produce postsurgical analgesia.

Efficacy and Safety
The efficacy of Dermapar was compared to placebo in two multicenter, randomized, double-blinded clinical trials conducted in a soft tissue (excisional hemorrhoidectomy) and an orthopedic (bunionectomy) surgical model.
The safety of Dermapar has been evaluated in 21 clinical trials which include over 1300 subjects in the safety database.
Dermapar administered locally into the surgical site was evaluated in 10 randomized, double-blind clinical studies involving 823 patients undergoing various surgical procedures. Patients were administered a dose ranging from 66 mg to 532 mg of Dermapar.

Dermapar® (bupivacaine liposome injectable suspension) is available in single-use vials for local administration
20 mL vial, 1.3% (13.3 mg/mL) packaged in cartons of 10

NEW SINGLE-DOSE, NON-OPIOID DERMAPAR®
(Bupivacaine Liposome Injectable Suspension)
ENHANCING POSTSURGICAL PAIN CONTROL

Food and Drug Administration (FDA) approved .Prescription Only (POM)

A Taj Pharma"India Product